A Pharmacometrics‐Informed Trial Simulation Framework for Optimizing Study Designs for Disease‐Modifying Treatments in Rare Neurological Disorders
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70082 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Yevgen Ryeznik und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Rare Diseases, Research Design, Nervous System Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The development of new treatments for rare neurological diseases (RNDs) may be very challenging due to limited natural history data, lack of relevant biomarkers and clinical endpoints, small and heterogeneous patient populations, and other complexities. A systematic approach is needed for comparing various design and analysis strategies to identify “optimal” approaches for a clinical trial in a chosen RND with the given resource constraints. For this purpose, we propose a pharmacometrics‐informed clinical scenario evaluation framework (CSE‐PMx), which includes some important research hallmarks relevant to RND clinical trials: a disease progression model for simulating individual longitudinal outcomes, the choice of a suitable randomization method for trial design, and an option to perform subsequent statistical analysis with randomization tests. We illustrate the utility of CSE‐PMx for an exemplary randomized trial to compare the disease‐modifying effect of an experimental treatment versus control in patients with Autosomal‐Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS). In the considered example, our simulation evidence suggests that a nonlinear mixed‐effects model (NLMEM) with a population‐based likelihood ratio test analysis is valid, robust, and more powerful than some conventional methods such as two‐sample t ‐test, analysis of covariance (ANCOVA), or a mixed model with repeated measurements (MMRM). Our proposed framework is very flexible and generalizable to clinical research in other rare disease indications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Department of Medical Statistics, RWTH Aachen University, Aachen, Germany.
- Medical School, Sigmund Freud Private University, Vienna, Austria.
- Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France.
- Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en santé, Environnement et Travail) UMR_S 1085, Rennes, France.
- Division Translational Genomics of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Tübingen, Germany.
ORCID-Profile: Yevgen Ryeznik, Ralf-Dieter Hilgers, Nicole Heussen, Emmanuelle Comets, France Mentré, Niels Hendrickx, Mats O Karlsson, Andrew C Hooker, Alzahra Hamdan, Xiaomei Chen, Rebecca Schüle, Matthis Synofzik, Oleksandr Sverdlov
Zitieren
APA
Ryeznik, Y., Hilgers, R. D., Heussen, N., Comets, E., Mentré, F., Hendrickx, N., Karlsson, M. O., Hooker, A. C., Hamdan, A., Chen, X., Schüle, R., Synofzik, M., & Sverdlov, O. (2025). A Pharmacometrics‐Informed Trial Simulation Framework for Optimizing Study Designs for Disease‐Modifying Treatments in Rare Neurological Disorders. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70082
Vancouver
Ryeznik Y, Hilgers RD, Heussen N, Comets E, Mentré F, Hendrickx N, et al. A Pharmacometrics‐Informed Trial Simulation Framework for Optimizing Study Designs for Disease‐Modifying Treatments in Rare Neurological Disorders. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70082
BibTeX
@article{Ryeznik2025,
author = {Ryeznik, Yevgen and Hilgers, Ralf-Dieter and Heussen, Nicole and Comets, Emmanuelle and Mentré, France and Hendrickx, Niels and Karlsson, Mats O and Hooker, Andrew C and Hamdan, Alzahra and Chen, Xiaomei and Schüle, Rebecca and Synofzik, Matthis and Sverdlov, Oleksandr},
title = {A Pharmacometrics‐Informed Trial Simulation Framework for Optimizing Study Designs for Disease‐Modifying Treatments in Rare Neurological Disorders},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70082}
}
EUVIMED